tooluniverse-pharmacovigilance

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Pharmacovigilance Safety Analyzer

药物警戒安全分析器

Systematic drug safety analysis using FAERS adverse event data, FDA labeling, PharmGKB pharmacogenomics, and clinical trial safety signals.
KEY PRINCIPLES:
  1. Report-first approach - Create report file FIRST, update progressively
  2. Signal quantification - Use disproportionality measures (PRR, ROR)
  3. Severity stratification - Prioritize serious/fatal events
  4. Multi-source triangulation - FAERS, labels, trials, literature
  5. Pharmacogenomic context - Include genetic risk factors
  6. Actionable output - Risk-benefit summary with recommendations
  7. English-first queries - Always use English drug names and search terms in tool calls, even if the user writes in another language. Only try original-language terms as a fallback. Respond in the user's language

利用FAERS不良事件数据、FDA标签、PharmGKB药物基因组学和临床试验安全信号进行系统化药物安全分析。
核心原则:
  1. 报告优先方法 - 首先创建报告文件,逐步更新内容
  2. 信号量化 - 使用不相称性指标(PRR、ROR)
  3. 严重程度分层 - 优先处理严重/致命事件
  4. 多源三角验证 - 结合FAERS、标签、试验、文献数据
  5. 药物基因组学背景 - 纳入遗传风险因素
  6. 可落地输出 - 包含建议的风险获益总结
  7. 英文优先查询 - 即使用户使用其他语言提问,工具调用时始终使用英文药物名称和搜索词,仅在失败时尝试原语言术语。用用户的语言回复

When to Use

使用场景

Apply when user asks:
  • "What are the safety concerns for [drug]?"
  • "What adverse events are associated with [drug]?"
  • "Is [drug] safe? What are the risks?"
  • "Should I be concerned about [specific adverse event] with [drug]?"
  • "Compare safety profiles of [drug A] vs [drug B]"
  • "Pharmacovigilance analysis for [drug]"

当用户提出以下问题时适用:
  • "[药物名称]有哪些安全隐患?"
  • "[药物名称]会引发哪些不良事件?"
  • "[药物名称]安全吗?有哪些风险?"
  • "使用[药物名称]时,我需要担心[特定不良事件]吗?"
  • "对比[药物A]和[药物B]的安全性特征"
  • "对[药物名称]进行药物警戒分析"

Critical Workflow Requirements

关键工作流要求

1. Report-First Approach (MANDATORY)

1. 报告优先方法(强制要求)

  1. Create the report file FIRST:
    • File name:
      [DRUG]_safety_report.md
    • Initialize with all section headers
    • Add placeholder text:
      [Researching...]
  2. Progressively update as you gather data
  3. Output separate data files:
    • [DRUG]_adverse_events.csv
      - Ranked AEs with counts/signals
    • [DRUG]_pharmacogenomics.csv
      - PGx variants and recommendations
  1. 首先创建报告文件:
    • 文件名:
      [DRUG]_safety_report.md
    • 初始化所有章节标题
    • 添加占位文本:
      [研究中...]
  2. 收集数据时逐步更新
  3. 输出独立数据文件:
    • [DRUG]_adverse_events.csv
      - 带计数/信号的不良事件排名表
    • [DRUG]_pharmacogenomics.csv
      - 药物基因组学变异体及建议

2. Citation Requirements (MANDATORY)

2. 引用要求(强制要求)

Every safety signal MUST include source:
markdown
undefined
每个安全信号必须包含来源:
markdown
undefined

Signal: Hepatotoxicity

信号: 肝毒性

  • PRR: 3.2 (95% CI: 2.8-3.7)
  • Cases: 1,247 reports
  • Serious: 892 (71.5%)
  • Fatal: 23
Source: FAERS via
FAERS_count_reactions_by_drug_event
(Q1 2020 - Q4 2025)

---
  • PRR: 3.2 (95% CI: 2.8-3.7)
  • 案例数: 1,247份报告
  • 严重事件: 892例(71.5%)
  • 致命事件: 23例
来源: FAERS via
FAERS_count_reactions_by_drug_event
(2020年第一季度 - 2025年第四季度)

---

Phase 0: Tool Verification

工具验证阶段

CRITICAL: Verify tool parameters before calling.
关键: 调用工具前先验证参数。

Known Parameter Corrections

已知参数修正

ToolWRONG ParameterCORRECT Parameter
FAERS_count_reactions_by_drug_event
drug
drug_name
DailyMed_search_spls
name
drug_name
PharmGKB_search_drug
drug
query
OpenFDA_get_drug_events
drug_name
search

工具错误参数正确参数
FAERS_count_reactions_by_drug_event
drug
drug_name
DailyMed_search_spls
name
drug_name
PharmGKB_search_drug
drug
query
OpenFDA_get_drug_events
drug_name
search

Workflow Overview

工作流概览

Phase 1: Drug Disambiguation
├── Resolve drug name (brand → generic)
├── Get identifiers (RxCUI, ChEMBL, DrugBank)
└── Identify drug class and mechanism
Phase 2: Adverse Event Profiling (FAERS)
├── Query FAERS for drug-event pairs
├── Calculate disproportionality (PRR, ROR)
├── Stratify by seriousness
└── OUTPUT: Ranked AE table
Phase 3: Label Warning Extraction
├── DailyMed boxed warnings
├── Contraindications
├── Warnings and precautions
└── OUTPUT: Label safety summary
Phase 4: Pharmacogenomic Risk
├── PharmGKB clinical annotations
├── High-risk genotypes
├── Dosing recommendations
└── OUTPUT: PGx risk table
Phase 5: Clinical Trial Safety
├── ClinicalTrials.gov safety data
├── Phase 3/4 discontinuation rates
├── Serious AEs in trials
└── OUTPUT: Trial safety summary
Phase 5.5: Pathway & Mechanism Context (NEW)
├── KEGG: Drug metabolism pathways
├── Reactome: Mechanism-linked pathways
├── Target pathway analysis
└── OUTPUT: Mechanistic safety context
Phase 5.6: Literature Intelligence (ENHANCED)
├── PubMed: Published safety studies
├── BioRxiv/MedRxiv: Recent preprints
├── OpenAlex: Citation analysis
└── OUTPUT: Literature evidence
Phase 6: Signal Prioritization
├── Rank by PRR × severity × frequency
├── Identify actionable signals
├── Risk-benefit assessment
└── OUTPUT: Prioritized signal list
Phase 7: Report Synthesis

阶段1: 药物身份解析
├── 解析药物名称(品牌名→通用名)
├── 获取标识符(RxCUI、ChEMBL、DrugBank)
└── 识别药物类别和作用机制
阶段2: 不良事件特征分析(FAERS)
├── 查询FAERS获取药物-事件对
├── 计算不相称性指标(PRR、ROR)
├── 按严重程度分层
└── 输出: 不良事件排名表
阶段3: 标签警告提取
├── DailyMed黑框警告
├── 禁忌症
├── 警告与注意事项
└── 输出: 标签安全总结
阶段4: 药物基因组学风险
├── PharmGKB临床注释
├── 高风险基因型
├── 给药建议
└── 输出: 药物基因组学风险表
阶段5: 临床试验安全性
├── ClinicalTrials.gov安全数据
├── 3/4期试验停药率
├── 试验中的严重不良事件
└── 输出: 试验安全总结
阶段5.5: 通路与机制背景(新增)
├── KEGG: 药物代谢通路
├── Reactome: 机制关联通路
├── 靶点通路分析
└── 输出: 机制性安全背景
阶段5.6: 文献情报(增强版)
├── PubMed: 已发表的安全性研究
├── BioRxiv/MedRxiv: 最新预印本
├── OpenAlex: 引用分析
└── 输出: 文献证据
阶段6: 信号优先级排序
├── 按PRR × 严重程度 × 频率排名
├── 识别可落地信号
├── 风险获益评估
└── 输出: 优先级信号列表
阶段7: 报告合成

Phase 1: Drug Disambiguation

阶段1: 药物身份解析

1.1 Resolve Drug Identity

1.1 确认药物身份

python
def resolve_drug(tu, drug_query):
    """Resolve drug name to standardized identifiers."""
    identifiers = {}
    
    # DailyMed for NDC and SPL
    dailymed = tu.tools.DailyMed_search_spls(drug_name=drug_query)
    if dailymed:
        identifiers['ndc'] = dailymed[0].get('ndc')
        identifiers['setid'] = dailymed[0].get('setid')
        identifiers['generic_name'] = dailymed[0].get('generic_name')
    
    # ChEMBL for molecule data
    chembl = tu.tools.ChEMBL_search_drugs(query=drug_query)
    if chembl:
        identifiers['chembl_id'] = chembl[0].get('molecule_chembl_id')
        identifiers['max_phase'] = chembl[0].get('max_phase')
    
    return identifiers
python
def resolve_drug(tu, drug_query):
    """将药物名称解析为标准化标识符。"""
    identifiers = {}
    
    # 通过DailyMed获取NDC和SPL
    dailymed = tu.tools.DailyMed_search_spls(drug_name=drug_query)
    if dailymed:
        identifiers['ndc'] = dailymed[0].get('ndc')
        identifiers['setid'] = dailymed[0].get('setid')
        identifiers['generic_name'] = dailymed[0].get('generic_name')
    
    # 通过ChEMBL获取分子数据
    chembl = tu.tools.ChEMBL_search_drugs(query=drug_query)
    if chembl:
        identifiers['chembl_id'] = chembl[0].get('molecule_chembl_id')
        identifiers['max_phase'] = chembl[0].get('max_phase')
    
    return identifiers

1.2 Output for Report

1.2 报告输出示例

markdown
undefined
markdown
undefined

1. Drug Identification

1. 药物识别信息

PropertyValue
Generic NameMetformin
Brand NamesGlucophage, Fortamet, Glumetza
Drug ClassBiguanide antidiabetic
ChEMBL IDCHEMBL1431
MechanismAMPK activator, hepatic gluconeogenesis inhibitor
First Approved1994 (US)
Source: DailyMed via
DailyMed_search_spls
, ChEMBL

---
属性
通用名二甲双胍
品牌名Glucophage、Fortamet、Glumetza
药物类别双胍类降糖药
ChEMBL IDCHEMBL1431
作用机制AMPK激活剂、肝糖异生抑制剂
首次获批时间1994年(美国)
来源: DailyMed via
DailyMed_search_spls
, ChEMBL

---

Phase 2: Adverse Event Profiling

阶段2: 不良事件特征分析

2.1 FAERS Query Strategy

2.1 FAERS查询策略

python
def get_faers_events(tu, drug_name, top_n=50):
    """Query FAERS for adverse events."""
    
    # Get event counts
    events = tu.tools.FAERS_count_reactions_by_drug_event(
        drug_name=drug_name,
        limit=top_n
    )
    
    # For each event, get detailed breakdown
    detailed_events = []
    for event in events:
        detail = tu.tools.FAERS_get_event_details(
            drug_name=drug_name,
            reaction=event['reaction']
        )
        detailed_events.append({
            'reaction': event['reaction'],
            'count': event['count'],
            'serious': detail.get('serious_count', 0),
            'fatal': detail.get('death_count', 0),
            'hospitalization': detail.get('hospitalization_count', 0)
        })
    
    return detailed_events
python
def get_faers_events(tu, drug_name, top_n=50):
    """查询FAERS获取不良事件数据。"""
    
    # 获取事件计数
    events = tu.tools.FAERS_count_reactions_by_drug_event(
        drug_name=drug_name,
        limit=top_n
    )
    
    # 为每个事件获取详细分类
    detailed_events = []
    for event in events:
        detail = tu.tools.FAERS_get_event_details(
            drug_name=drug_name,
            reaction=event['reaction']
        )
        detailed_events.append({
            'reaction': event['reaction'],
            'count': event['count'],
            'serious': detail.get('serious_count', 0),
            'fatal': detail.get('death_count', 0),
            'hospitalization': detail.get('hospitalization_count', 0)
        })
    
    return detailed_events

2.2 Disproportionality Analysis

2.2 不相称性分析

Proportional Reporting Ratio (PRR):
PRR = (A/B) / (C/D)

Where:
A = Reports of drug X with event Y
B = Reports of drug X with any event
C = Reports of event Y with any drug (excluding X)
D = Total reports (excluding drug X)
Signal Thresholds:
MeasureSignal ThresholdStrong Signal
PRR>2.0>3.0
Chi-squared>4.0>10.0
N (case count)≥3≥10
比例报告比(PRR):
PRR = (A/B) / (C/D)

其中:
A = 药物X发生事件Y的报告数
B = 药物X发生任何事件的报告数
C = 除X外其他药物发生事件Y的报告数
D = 除X外的总报告数
信号阈值:
指标信号阈值强信号
PRR>2.0>3.0
卡方值>4.0>10.0
案例数N≥3≥10

2.3 Severity Classification

2.3 严重程度分类

CategoryDefinitionPriority
FatalDeath outcomeHighest
Life-threateningImmediate death riskVery High
HospitalizationRequired/prolonged hospitalizationHigh
DisabilityPersistent impairmentHigh
Congenital anomalyBirth defectHigh
Other seriousMedical intervention requiredMedium
Non-seriousNo serious criteriaLow
类别定义优先级
致命死亡结局最高
危及生命存在即时死亡风险极高
住院需要/延长住院时间
残疾持续性功能障碍
先天异常出生缺陷
其他严重事件需要医学干预
非严重事件不满足严重事件标准

2.4 Output for Report

2.4 报告输出示例

markdown
undefined
markdown
undefined

2. Adverse Event Profile (FAERS)

2. 不良事件特征(FAERS)

Data Period: Q1 2020 - Q4 2025 Total Reports for Drug: 45,234
数据周期: 2020年第一季度 - 2025年第四季度 药物总报告数: 45,234

2.1 Top Adverse Events by Frequency

2.1 按频率排序的Top不良事件

RankAdverse EventReportsPRR95% CISerious (%)Fatal
1Diarrhea8,2342.32.1-2.512%3
2Nausea6,8921.81.6-2.08%0
3Lactic acidosis1,24715.212.8-17.989% ⚠️156 ⚠️
4Hypoglycemia2,3412.11.9-2.434%8
5Vitamin B12 deficiency8928.47.2-9.823%0
排名不良事件报告数PRR95%置信区间严重事件占比致命事件数
1腹泻8,2342.32.1-2.512%3
2恶心6,8921.81.6-2.08%0
3乳酸性酸中毒1,24715.212.8-17.989% ⚠️156 ⚠️
4低血糖2,3412.11.9-2.434%8
5维生素B12缺乏8928.47.2-9.823%0

2.2 Serious Adverse Events Only

2.2 仅严重不良事件

Adverse EventSerious ReportsFatalPRRSignal
Lactic acidosis1,11015615.2STRONG ⚠️
Acute kidney injury678344.2Moderate
Hepatotoxicity234123.1Moderate
不良事件严重事件报告数致命事件数PRR信号强度
乳酸性酸中毒1,11015615.2强信号 ⚠️
急性肾损伤678344.2中等
肝毒性234123.1中等

2.3 Signal Interpretation

2.3 信号解读

Strong Signal: Lactic Acidosis ⚠️
  • PRR of 15.2 indicates 15x higher reporting rate than expected
  • 89% classified as serious
  • 156 fatalities (12.5% case fatality)
  • Known class effect of biguanides
  • Risk factors: renal impairment, hypoxia, contrast agents
Source: FAERS via
FAERS_count_reactions_by_drug_event

---
强信号: 乳酸性酸中毒 ⚠️
  • PRR为15.2,意味着报告率比预期高15倍
  • 89%被归类为严重事件
  • 156例死亡(病例死亡率12.5%)
  • 双胍类药物的已知类别效应
  • 风险因素: 肾功能损害、缺氧、造影剂
来源: FAERS via
FAERS_count_reactions_by_drug_event

---

Phase 3: Label Warning Extraction

阶段3: 标签警告提取

3.1 DailyMed Query

3.1 DailyMed查询

python
def extract_label_warnings(tu, setid):
    """Extract safety sections from FDA label."""
    
    label = tu.tools.DailyMed_get_spl_by_set_id(setid=setid)
    
    warnings = {
        'boxed_warning': label.get('boxed_warning'),
        'contraindications': label.get('contraindications'),
        'warnings_precautions': label.get('warnings_and_precautions'),
        'adverse_reactions': label.get('adverse_reactions'),
        'drug_interactions': label.get('drug_interactions')
    }
    
    return warnings
python
def extract_label_warnings(tu, setid):
    """从FDA标签中提取安全相关章节。"""
    
    label = tu.tools.DailyMed_get_spl_by_set_id(setid=setid)
    
    warnings = {
        'boxed_warning': label.get('boxed_warning'),
        'contraindications': label.get('contraindications'),
        'warnings_precautions': label.get('warnings_and_precautions'),
        'adverse_reactions': label.get('adverse_reactions'),
        'drug_interactions': label.get('drug_interactions')
    }
    
    return warnings

3.2 Warning Severity Categories

3.2 警告严重程度类别

CategorySymbolDescription
Boxed WarningMost serious, life-threatening
Contraindication🔴Must not use
Warning🟠Significant risk
Precaution🟡Use caution
类别符号描述
黑框警告最严重、危及生命
禁忌症🔴绝对禁止使用
警告🟠显著风险
注意事项🟡需谨慎使用

3.3 Output for Report

3.3 报告输出示例

markdown
undefined
markdown
undefined

3. FDA Label Safety Information

3. FDA标签安全信息

3.1 Boxed Warning ⬛

3.1 黑框警告 ⬛

LACTIC ACIDOSIS
Metformin can cause lactic acidosis, a rare but serious complication. Risk increases with renal impairment, sepsis, dehydration, excessive alcohol intake, hepatic impairment, and acute heart failure.
Contraindicated in patients with eGFR <30 mL/min/1.73m²
乳酸性酸中毒
二甲双胍可能引发乳酸性酸中毒,这是一种罕见但严重的并发症。 肾功能损害、败血症、脱水、过量饮酒、肝功能损害和急性心力衰竭会增加风险。
eGFR <30 mL/min/1.73m²的患者禁用

3.2 Contraindications 🔴

3.2 禁忌症 🔴

ContraindicationRationale
eGFR <30 mL/min/1.73m²Lactic acidosis risk
Acute/chronic metabolic acidosisMay worsen acidosis
Hypersensitivity to metforminAllergic reaction
禁忌症理由
eGFR <30 mL/min/1.73m²乳酸性酸中毒风险
急性/慢性代谢性酸中毒可能加重酸中毒
对二甲双胍过敏过敏反应

3.3 Warnings and Precautions 🟠

3.3 警告与注意事项 🟠

WarningClinical Action
Vitamin B12 deficiencyMonitor B12 levels annually
Hypoglycemia with insulinReduce insulin dose
Radiologic contrastHold 48h around procedure
Surgical proceduresHold day of surgery
Source: DailyMed via
DailyMed_get_spl_by_set_id

---
警告临床措施
维生素B12缺乏每年监测B12水平
与胰岛素联用引发低血糖减少胰岛素剂量
放射造影剂检查前后48小时停药
手术手术当日停药
来源: DailyMed via
DailyMed_get_spl_by_set_id

---

Phase 4: Pharmacogenomic Risk

阶段4: 药物基因组学风险

4.1 PharmGKB Query

4.1 PharmGKB查询

python
def get_pharmacogenomics(tu, drug_name):
    """Get pharmacogenomic annotations."""
    
    # Search PharmGKB
    pgx = tu.tools.PharmGKB_search_drug(query=drug_name)
    
    annotations = []
    for result in pgx:
        if result.get('clinical_annotation'):
            annotations.append({
                'gene': result['gene'],
                'variant': result['variant'],
                'phenotype': result['phenotype'],
                'recommendation': result['recommendation'],
                'level': result['level_of_evidence']
            })
    
    return annotations
python
def get_pharmacogenomics(tu, drug_name):
    """获取药物基因组学注释信息。"""
    
    # 查询PharmGKB
    pgx = tu.tools.PharmGKB_search_drug(query=drug_name)
    
    annotations = []
    for result in pgx:
        if result.get('clinical_annotation'):
            annotations.append({
                'gene': result['gene'],
                'variant': result['variant'],
                'phenotype': result['phenotype'],
                'recommendation': result['recommendation'],
                'level': result['level_of_evidence']
            })
    
    return annotations

4.2 PGx Evidence Levels

4.2 药物基因组学证据等级

LevelDescriptionClinical Action
1ACPIC/DPWG guideline, implementableFollow guideline
1BCPIC/DPWG guideline, annotationConsider testing
2AVIP annotation, moderate evidenceMay inform
2BVIP annotation, weaker evidenceResearch
3Low-level annotationNot actionable
等级描述临床措施
1ACPIC/DPWG指南,可直接落地遵循指南
1BCPIC/DPWG指南,注释类考虑检测
2AVIP注释,中等证据可参考
2BVIP注释,较弱证据研究用途
3低水平注释无落地价值

4.3 Output for Report

4.3 报告输出示例

markdown
undefined
markdown
undefined

4. Pharmacogenomic Risk Factors

4. 药物基因组学风险因素

4.1 Clinically Actionable Variants

4.1 临床可落地变异体

GeneVariantPhenotypeRecommendationLevel
SLC22A1rs628031Reduced OCT1Reduced metformin response2A
SLC22A1rs36056065Loss of functionConsider alternative2A
ATMrs11212617Increased responseStandard dosing3
基因变异体表型建议证据等级
SLC22A1rs628031OCT1功能降低二甲双胍反应性降低2A
SLC22A1rs36056065功能丧失考虑替代药物2A
ATMrs11212617反应性增强标准剂量3

4.2 Clinical Implications

4.2 临床意义

OCT1 (SLC22A1) Poor Metabolizers:
  • ~9% of Caucasians carry two loss-of-function alleles
  • Reduced hepatic uptake of metformin
  • May have decreased efficacy
  • Consider higher doses or alternative agent
No CPIC/DPWG guidelines currently exist for metformin
Source: PharmGKB via
PharmGKB_search_drug

---
OCT1 (SLC22A1) 弱代谢者:
  • 约9%的白种人携带两个功能丧失等位基因
  • 二甲双胍肝脏摄取减少
  • 疗效可能降低
  • 考虑增加剂量或更换药物
目前尚无针对二甲双胍的CPIC/DPWG指南
来源: PharmGKB via
PharmGKB_search_drug

---

Phase 5: Clinical Trial Safety

阶段5: 临床试验安全性

5.1 ClinicalTrials.gov Query

5.1 ClinicalTrials.gov查询

python
def get_trial_safety(tu, drug_name):
    """Get safety data from clinical trials."""
    
    # Search completed phase 3/4 trials
    trials = tu.tools.search_clinical_trials(
        intervention=drug_name,
        phase="Phase 3",
        status="Completed",
        pageSize=20
    )
    
    safety_data = []
    for trial in trials:
        if trial.get('results_posted'):
            results = tu.tools.get_clinical_trial_results(
                nct_id=trial['nct_id']
            )
            safety_data.append(results.get('adverse_events'))
    
    return safety_data
python
def get_trial_safety(tu, drug_name):
    """从临床试验中获取安全数据。"""
    
    # 搜索已完成的3/4期试验
    trials = tu.tools.search_clinical_trials(
        intervention=drug_name,
        phase="Phase 3",
        status="Completed",
        pageSize=20
    )
    
    safety_data = []
    for trial in trials:
        if trial.get('results_posted'):
            results = tu.tools.get_clinical_trial_results(
                nct_id=trial['nct_id']
            )
            safety_data.append(results.get('adverse_events'))
    
    return safety_data

5.2 Output for Report

5.2 报告输出示例

markdown
undefined
markdown
undefined

5. Clinical Trial Safety Data

5. 临床试验安全数据

5.1 Phase 3 Trial Summary

5.1 3期试验总结

TrialNDurationSerious AEs (Drug)Serious AEs (Placebo)Deaths
UKPDS1,70410 yr12.3%14.1%8.2% vs 9.1%
DPP1,0733 yr4.2%3.8%0.1%
SPREAD8842 yr5.1%4.9%0.2%
试验样本量持续时间试验组严重不良事件率安慰剂组严重不良事件率死亡率
UKPDS1,70410年12.3%14.1%8.2% vs 9.1%
DPP1,0733年4.2%3.8%0.1%
SPREAD8842年5.1%4.9%0.2%

5.2 Common Adverse Events in Trials

5.2 试验中常见不良事件

Adverse EventDrug (%)Placebo (%)Difference
Diarrhea53%12%+41% ⚠️
Nausea26%8%+18%
Flatulence12%6%+6%
Asthenia9%6%+3%
Source: ClinicalTrials.gov via
search_clinical_trials

---
不良事件试验组发生率安慰剂组发生率差异
腹泻53%12%+41% ⚠️
恶心26%8%+18%
胃肠胀气12%6%+6%
乏力9%6%+3%
来源: ClinicalTrials.gov via
search_clinical_trials

---

Phase 5.5: Pathway & Mechanism Context (NEW)

阶段5.5: 通路与机制背景(新增)

5.5.1 Drug Metabolism Pathways (KEGG)

5.5.1 药物代谢通路(KEGG)

python
def get_drug_pathway_context(tu, drug_name, drug_targets):
    """Get pathway context for mechanistic safety understanding."""
    
    # KEGG drug metabolism
    metabolism = tu.tools.kegg_search_pathway(
        query=f"{drug_name} metabolism"
    )
    
    # Target pathways
    target_pathways = {}
    for target in drug_targets:
        pathways = tu.tools.kegg_get_gene_info(gene_id=f"hsa:{target}")
        target_pathways[target] = pathways.get('pathways', [])
    
    return {
        'metabolism_pathways': metabolism,
        'target_pathways': target_pathways
    }
python
def get_drug_pathway_context(tu, drug_name, drug_targets):
    """获取机制性安全理解的通路背景。"""
    
    # KEGG: 药物代谢
    metabolism = tu.tools.kegg_search_pathway(
        query=f"{drug_name} metabolism"
    )
    
    # 靶点通路
    target_pathways = {}
    for target in drug_targets:
        pathways = tu.tools.kegg_get_gene_info(gene_id=f"hsa:{target}")
        target_pathways[target] = pathways.get('pathways', [])
    
    return {
        'metabolism_pathways': metabolism,
        'target_pathways': target_pathways
    }

5.5.2 Output for Report

5.5.2 报告输出示例

markdown
undefined
markdown
undefined

5.5 Pathway & Mechanism Context

5.5 通路与机制背景

Drug Metabolism Pathways (KEGG)

药物代谢通路(KEGG)

PathwayRelevanceSafety Implication
Drug metabolism - cytochrome P450Primary metabolismCYP2C9 interactions
Gluconeogenesis inhibitionMOALactic acidosis mechanism
Mitochondrial complex IOff-targetLactic acid accumulation
通路相关性安全意义
药物代谢-细胞色素P450主要代谢途径CYP2C9相互作用
糖异生抑制作用机制乳酸性酸中毒机制
线粒体复合物I脱靶效应乳酸堆积

Target Pathway Analysis

靶点通路分析

Primary Target: AMPK
  • Pathway: AMPK signaling (hsa04152)
  • Downstream: mTOR inhibition, autophagy
  • Safety relevance: Explains metabolic effects
Mechanistic Basis for Key AEs:
Adverse EventPathway Mechanism
Lactic acidosisMitochondrial complex I inhibition
GI intoleranceSerotonin release in gut
B12 deficiencyIntrinsic factor interference
Source: KEGG, Reactome

---
主要靶点: AMPK
  • 通路: AMPK信号通路(hsa04152)
  • 下游: mTOR抑制、自噬
  • 安全相关性: 解释代谢效应
关键不良事件的机制基础:
不良事件通路机制
乳酸性酸中毒线粒体复合物I抑制
胃肠道不耐受肠道5-羟色胺释放
B12缺乏内因子干扰
来源: KEGG, Reactome

---

Phase 5.6: Literature Intelligence (ENHANCED)

阶段5.6: 文献情报(增强版)

5.6.1 Published Safety Studies

5.6.1 已发表的安全性研究

python
def comprehensive_safety_literature(tu, drug_name, key_aes):
    """Search all literature sources for safety evidence."""
    
    # PubMed: Peer-reviewed
    pubmed = tu.tools.PubMed_search_articles(
        query=f'"{drug_name}" AND (safety OR adverse OR toxicity)',
        limit=30
    )
    
    # BioRxiv: Preprints
    biorxiv = tu.tools.BioRxiv_search_preprints(
        query=f"{drug_name} mechanism toxicity",
        limit=10
    )
    
    # MedRxiv: Clinical preprints
    medrxiv = tu.tools.MedRxiv_search_preprints(
        query=f"{drug_name} safety",
        limit=10
    )
    
    # Citation analysis for key papers
    key_papers = pubmed[:10]
    for paper in key_papers:
        citation = tu.tools.openalex_search_works(
            query=paper['title'],
            limit=1
        )
        paper['citations'] = citation[0].get('cited_by_count', 0) if citation else 0
    
    return {
        'pubmed': pubmed,
        'preprints': biorxiv + medrxiv,
        'key_papers': key_papers
    }
python
def comprehensive_safety_literature(tu, drug_name, key_aes):
    """搜索所有文献来源获取安全证据。"""
    
    # PubMed: 同行评审文献
    pubmed = tu.tools.PubMed_search_articles(
        query=f'"{drug_name}" AND (safety OR adverse OR toxicity)',
        limit=30
    )
    
    # BioRxiv: 预印本
    biorxiv = tu.tools.BioRxiv_search_preprints(
        query=f"{drug_name} mechanism toxicity",
        limit=10
    )
    
    # MedRxiv: 临床预印本
    medrxiv = tu.tools.MedRxiv_search_preprints(
        query=f"{drug_name} safety",
        limit=10
    )
    
    # 关键论文的引用分析
    key_papers = pubmed[:10]
    for paper in key_papers:
        citation = tu.tools.openalex_search_works(
            query=paper['title'],
            limit=1
        )
        paper['citations'] = citation[0].get('cited_by_count', 0) if citation else 0
    
    return {
        'pubmed': pubmed,
        'preprints': biorxiv + medrxiv,
        'key_papers': key_papers
    }

5.6.2 Output for Report

5.6.2 报告输出示例

markdown
undefined
markdown
undefined

5.6 Literature Evidence

5.6 文献证据

Key Safety Studies

关键安全性研究

PMIDTitleYearCitationsFinding
29234567Metformin and lactic acidosis: meta-analysis2020245Risk 4.3/100,000
28765432Long-term cardiovascular outcomes...2019567CV benefit confirmed
30123456B12 deficiency prevalence study202112330% after 4 years
PMID标题年份引用数发现
29234567二甲双胍与乳酸性酸中毒: 荟萃分析2020245风险4.3/100,000
28765432长期心血管结局...2019567心血管获益得到确认
30123456B12缺乏患病率研究20211234年后患病率30%

Recent Preprints (Not Peer-Reviewed)

最新预印本(未经过同行评审)

SourceTitlePostedRelevance
MedRxivNovel metformin safety signal in elderly2024-01Age-related risk
BioRxivGut microbiome and metformin GI effects2024-02Mechanistic
⚠️ Note: Preprints have NOT undergone peer review.
来源标题发布日期相关性
MedRxiv老年人群中二甲双胍的新安全信号2024-01年龄相关风险
BioRxiv肠道微生物组与二甲双胍胃肠道效应2024-02机制性研究
⚠️ 注意: 预印本未经过同行评审。

Evidence Summary

证据总结

Evidence TypeCountHigh-Impact
Systematic reviews125
RCTs with safety data288
Mechanistic studies153
Case reports45-
Source: PubMed, BioRxiv, MedRxiv, OpenAlex

---
证据类型数量高影响力
系统综述125
含安全数据的随机对照试验288
机制性研究153
病例报告45-
来源: PubMed, BioRxiv, MedRxiv, OpenAlex

---

Phase 6: Signal Prioritization

阶段6: 信号优先级排序

6.1 Signal Scoring Formula

6.1 信号评分公式

Signal Score = PRR × Severity_Weight × log10(Case_Count + 1)

Severity Weights:
- Fatal: 10
- Life-threatening: 8
- Hospitalization: 5
- Disability: 5
- Other serious: 3
- Non-serious: 1
信号评分 = PRR × 严重程度权重 × log10(案例数 + 1)

严重程度权重:
- 致命: 10
- 危及生命: 8
- 住院: 5
- 残疾: 5
- 其他严重事件: 3
- 非严重事件: 1

6.2 Output for Report

6.2 报告输出示例

markdown
undefined
markdown
undefined

6. Prioritized Safety Signals

6. 优先级安全信号

6.1 Critical Signals (Immediate Attention)

6.1 关键信号(需立即关注)

SignalPRRFatalScoreAction
Lactic acidosis15.2156482Boxed warning exists
Acute kidney injury4.23489Monitor renal function
信号PRR致命事件数评分措施
乳酸性酸中毒15.2156482已有黑框警告
急性肾损伤4.23489监测肾功能

6.2 Moderate Signals (Monitor)

6.2 中等信号(需监测)

SignalPRRSeriousScoreAction
Hepatotoxicity3.123452Check LFTs if symptoms
Pancreatitis2.817841Monitor lipase
信号PRR严重事件数评分措施
肝毒性3.123452出现症状时检查肝功能
胰腺炎2.817841监测脂肪酶

6.3 Known/Expected (Manage Clinically)

6.3 已知/预期事件(临床管理)

SignalPRRFrequencyManagement
Diarrhea2.318%Start low, titrate slow
Nausea1.812%Take with food
B12 deficiency8.42%Annual monitoring

---
信号PRR发生率管理措施
腹泻2.318%小剂量起始,缓慢加量
恶心1.812%随餐服用
B12缺乏8.42%每年监测

---

Report Template

报告模板

File:
[DRUG]_safety_report.md
markdown
undefined
文件:
[DRUG]_safety_report.md
markdown
undefined

Pharmacovigilance Safety Report: [DRUG]

药物警戒安全报告: [药物名称]

Generated: [Date] | Query: [Original query] | Status: In Progress

生成日期: [日期] | 查询内容: [原始查询] | 状态: 进行中

Executive Summary

执行摘要

[Researching...]

[研究中...]

1. Drug Identification

1. 药物识别信息

1.1 Drug Information

1.1 药物基本信息

[Researching...]

[研究中...]

2. Adverse Event Profile (FAERS)

2. 不良事件特征(FAERS)

2.1 Top Adverse Events

2.1 Top不良事件

[Researching...]
[研究中...]

2.2 Serious Adverse Events

2.2 严重不良事件

[Researching...]
[研究中...]

2.3 Signal Analysis

2.3 信号分析

[Researching...]

[研究中...]

3. FDA Label Safety Information

3. FDA标签安全信息

3.1 Boxed Warnings

3.1 黑框警告

[Researching...]
[研究中...]

3.2 Contraindications

3.2 禁忌症

[Researching...]
[研究中...]

3.3 Warnings and Precautions

3.3 警告与注意事项

[Researching...]

[研究中...]

4. Pharmacogenomic Risk Factors

4. 药物基因组学风险因素

4.1 Actionable Variants

4.1 可落地变异体

[Researching...]
[研究中...]

4.2 Testing Recommendations

4.2 检测建议

[Researching...]

[研究中...]

5. Clinical Trial Safety

5. 临床试验安全性

5.1 Trial Summary

5.1 试验总结

[Researching...]
[研究中...]

5.2 Adverse Events in Trials

5.2 试验中的不良事件

[Researching...]

[研究中...]

6. Prioritized Safety Signals

6. 优先级安全信号

6.1 Critical Signals

6.1 关键信号

[Researching...]
[研究中...]

6.2 Moderate Signals

6.2 中等信号

[Researching...]

[研究中...]

7. Risk-Benefit Assessment

7. 风险获益评估

[Researching...]

[研究中...]

8. Clinical Recommendations

8. 临床建议

8.1 Monitoring Recommendations

8.1 监测建议

[Researching...]
[研究中...]

8.2 Patient Counseling Points

8.2 患者宣教要点

[Researching...]
[研究中...]

8.3 Contraindication Checklist

8.3 禁忌症清单

[Researching...]

[研究中...]

9. Data Gaps & Limitations

9. 数据缺口与局限性

[Researching...]

[研究中...]

10. Data Sources

10. 数据来源

[Will be populated as research progresses...]

---
[将随研究进展逐步填充...]

---

Evidence Grading

证据分级

TierSymbolCriteriaExample
T1⚠️⚠️⚠️PRR >10, fatal outcomes, boxed warningLactic acidosis
T2⚠️⚠️PRR 3-10, serious outcomesHepatotoxicity
T3⚠️PRR 2-3, moderate concernHypoglycemia
T4ℹ️PRR <2, known/expectedGI side effects

层级符号标准示例
T1⚠️⚠️⚠️PRR>10、致命结局、黑框警告乳酸性酸中毒
T2⚠️⚠️PRR 3-10、严重结局肝毒性
T3⚠️PRR 2-3、中等关注低血糖
T4ℹ️PRR<2、已知/预期事件胃肠道副作用

Completeness Checklist

完整性检查清单

Phase 1: Drug Identification

阶段1: 药物识别

  • Generic name resolved
  • Brand names listed
  • Drug class identified
  • ChEMBL/DrugBank ID obtained
  • Mechanism of action stated
  • 通用名已解析
  • 品牌名已列出
  • 药物类别已识别
  • 已获取ChEMBL/DrugBank ID
  • 已说明作用机制

Phase 2: FAERS Analysis

阶段2: FAERS分析

  • ≥20 adverse events queried
  • PRR calculated for top events
  • Serious/fatal counts included
  • Signal thresholds applied
  • Time period stated
  • 已查询≥20种不良事件
  • 已为Top事件计算PRR
  • 已包含严重/致命事件计数
  • 已应用信号阈值
  • 已说明时间周期

Phase 3: Label Warnings

阶段3: 标签警告

  • Boxed warnings extracted (or "None")
  • Contraindications listed
  • Key warnings summarized
  • Drug interactions noted
  • 已提取黑框警告(或标注"无")
  • 已列出禁忌症
  • 已总结关键警告
  • 已记录药物相互作用

Phase 4: Pharmacogenomics

阶段4: 药物基因组学

  • PharmGKB queried
  • Actionable variants listed (or "None")
  • Evidence levels provided
  • Testing recommendations stated
  • 已查询PharmGKB
  • 已列出可落地变异体(或标注"无")
  • 已提供证据等级
  • 已说明检测建议

Phase 5: Clinical Trials

阶段5: 临床试验

  • Phase 3/4 trials searched
  • Serious AE rates compared
  • Discontinuation rates noted
  • 已搜索3/4期试验
  • 已对比严重不良事件发生率
  • 已记录停药率

Phase 6: Signal Prioritization

阶段6: 信号优先级排序

  • Signals ranked by score
  • Critical signals flagged
  • Actions recommended
  • 已按评分对信号排名
  • 已标记关键信号
  • 已给出建议措施

Phase 7-8: Synthesis

阶段7-8: 合成

  • Risk-benefit assessment provided
  • Monitoring recommendations listed
  • Patient counseling points included

  • 已提供风险获益评估
  • 已列出监测建议
  • 已包含患者宣教要点

Fallback Chains

备选工具链

Primary ToolFallback 1Fallback 2
FAERS_count_reactions_by_drug_event
OpenFDA_get_drug_events
Literature search
DailyMed_get_spl_by_set_id
FDA_drug_label_search
DailyMed website
PharmGKB_search_drug
CPIC_get_guidelines
Literature search
search_clinical_trials
ClinicalTrials.gov
API
PubMed for trial results

主工具备选工具1备选工具2
FAERS_count_reactions_by_drug_event
OpenFDA_get_drug_events
文献搜索
DailyMed_get_spl_by_set_id
FDA_drug_label_search
DailyMed官网
PharmGKB_search_drug
CPIC_get_guidelines
文献搜索
search_clinical_trials
ClinicalTrials.gov
API
PubMed试验结果搜索

Tool Reference

工具参考

See TOOLS_REFERENCE.md for complete tool documentation.
完整工具文档请参考 TOOLS_REFERENCE.md